Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome Clinical Trial

Official title:
A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRx (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

Status Completed

Clinical Trial Summary

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03360747
Study type	Interventional
Source	Akcea Therapeutics
Contact
Status	Completed
Phase	Phase 2
Start date	December 21, 2017
Completion date	September 4, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04223908` - InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia
Active, not recruiting	`NCT05130450` - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)	Phase 3
Completed	`NCT04568434` - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)	Phase 3
Completed	`NCT03912181` - Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes
Not yet recruiting	`NCT05902598` - A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome	Phase 3
Active, not recruiting	`NCT05185843` - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen	Phase 3
Completed	`NCT02658175` - The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome	Phase 3
Completed	`NCT02211209` - The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome	Phase 3
Available	`NCT06360237` - Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)